Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
6-METHYL-2(PROPANE-1-SULFONYL)-2H-THIENO[3,2-D][1,2,3]DIAZABORININ-1-OL is a boron-containing heterocyclic compound, specifically a sulfonylated diazaborine derivative with the molecular formula C₉H₁₃BN₂O₃S₂ and an average molecular mass of 272.146 g/mol. Its structure comprises a thieno-diazaborine core fused with a sulfonylpropane substituent and a methyl group. The compound is characterized by a boronate ester linkage, which confers unique electronic and steric properties critical for its biological activity. It acts as a potent inhibitor of bacterial enoyl-acyl carrier protein (ACP) reductase (ENR), a key enzyme in bacterial fatty acid biosynthesis. This inhibition disrupts the synthesis of bacterial cell membranes, leading to bacterial cell death. Due to this mechanism, it is being explored for potential therapeutic applications as an antibacterial agent, particularly against resistant strains of bacteria.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 6-METHYL-2(PROPANE-1-SULFONYL)-2H-THIENO[3,2-D][1,2,3]DIAZABORININ-1-OL.